PharPoint plans to utilise Medrio’s technology in all phases of clinical drug development from Phase I – IIIb studies as well as post marketing studies, registries and outcomes research. Medrio’s EDC system is fully compliant with 21 CFR Part 11, HIPAA, and other industry regulations.
Art Holmes, president and CEO at PharPoint Research, said: “The addition of Medrio’s EDC solution to our existing offerings further supports PharPoint’s ability to consistently exceed our client’s expectations. Medrio’s platform offers robust functionality and reduced study set-up times at an affordable cost, a combination not often seen in the EDC technology market.”
Mike Novotny, CEO of Medrio, said: “Medrio’s programmer-less configuration allows for an unrivaled time to launch that allows PharPoint to be highly responsive to customers. The combination of PharPoint’s industry leading services with Medrio’s EDC solution provides a compelling solution for organisations looking for a complete and cost-effective data management solution.”